AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17099309
Drug: Amuchina 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amuchina 10% solution
Trial: 12396323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DEC (6 mg/kg) and Albendazole (400 mg)
Trial: 7597431
Drug: Paclitaxel 170
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 170 mg/m2 followed by ifosfamide 5 g/m2 divided over 3 days with mesna
Trial: 724875
Drug: Directive therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directive therapy
Trial: 724875
Drug: Interpretative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpretative therapy
Trial: 23930635
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive Adper Prompt L-Pop
Trial: 21285943
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment (15 sessions separately for children and parents)
Trial: 18811602
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isotretinoin thrice a week for 3 months
Trial: 18811602
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of isotretinoin thrice a week for 3 months
Trial: 18811602
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 20 mg of isotretinoin
Trial: 17350990
Drug: lopinavir/ritonavir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir + saquinavir (400/100 mg + 800 mg)
Trial: 17350990
Drug: lopinavir/ritonavir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir + zidovudine/lamivudine (400/100 mg + 150/300 mg)
Trial: 17350990
Drug: lopinavir/ritonavir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir + saquinavir (600 or 800 mg)
Trial: 11883998
Drug: rhGH (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (13 IU/m(2) for 4 days) + glutamine-enriched TPN (7 g GLN/m(2)/day)
Trial: 9630144
Drug: Mixed endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed endurance and calisthenic/strength activities performed at a rapid pace three times weekly for 12 weeks
Trial: 8166318
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (10,000 lux for 30 min/day)
Trial: 8166318
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light therapy (500 lux for 30 min/day)
Trial: 8166318
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (10,000 lux for 30 min/day) in patients with seasonal bulimia
Trial: 8166318
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (10,000 lux for 30 min/day) in patients with nonseasonal bulimia
Trial: 3284292
Drug: Captopril (12.5‐25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5‐25 mg b.d.)
Trial: 28537969
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% solution (saline group)
Trial: 26625505
Drug: Co-payment reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-payment reduction from $8 to $0 per medication per month for antihypertensive prescriptions
Trial: 15690268
Drug: Fentanyl 20
RxNorm normalized name: fentaNYL 200 mcg buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 20 microg mixed with hyperbaric ropivacaine 10 mg (group FR10)
Trial: 15690268
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 15 mg (group R15)
Trial: 10569649
Drug: TNK-tPA 40
RxNorm normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNK-tPA 40 mg
Trial: 10569649
Drug: Mid-dose tertile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose tertile (0.40 to 0.51 mg/kg)
Trial: 10569649
Drug: High-dose tertile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tertile (0.52 to 1.24 mg/kg)
Trial: 10569649
Drug: Low-dose tertile
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tertile (0.2 to 0.39 mg/kg)
Trial: 10569649
Drug: High-dose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose and mid-dose tertiles
Trial: 1844195
Drug: Biological monitoring
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological monitoring (cervical mucus) for HCG administration
Trial: 1844195
Drug: Biochemical monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biochemical monitoring for HCG administration
Trial: 6996111
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (15 mg folic acid per day for 5 weeks)
Trial: 23415641
Drug: BRAF inhibitors
RxNorm normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF inhibitors
Trial: 31826931
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BRAF inhibition and TP53 reactivation
Trial: 31826931
Drug: Tissue-specific mutation–drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-specific mutation–drug associations
Trial: 28975664
Drug: Torasemide q24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide q24h (median dose = 0.24 mg/kg/d; range = 0.10–0.69 mg/kg/d)
Trial: 28975664
Drug: Furosemide q12h
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide q12h (median dose = 1.39 mg/kg q12h; range = 0.70–6.30 mg/kg q12h)
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type A SSNHL (acute in low tone frequencies) with FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type B SSNHL (acute in high tone frequencies) with FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type C SSNHL (acute in all frequencies) with FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type D SSNHL (total deafness) with FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type A SSNHL without FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type B SSNHL without FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type C SSNHL without FEF
Trial: 26695795
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for type D SSNHL without FEF
Trial: 23995661
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs)
Trial: 21411411
Drug: 1% Glechoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Glechoma hederacea extract lotion applied topically for 8 weeks
Trial: 19153829
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (L + C)
Trial: 11402116
Drug: Local methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local methylprednisolone injection (15 mg)
Trial: 11402116
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (low-dose, short-term)
Trial: 3525866
Drug: Diethylstilbestrol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (1 mg. 3 times daily)
Trial: 3525866
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (280 mg. twice daily for 8 weeks and 140 mg. twice daily thereafter)
Trial: 30304120
Drug: One implant
RxNorm normalized name: Testosterone Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One implant (GI)
Trial: 30304120
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants (GII)
Trial: 16648508
Drug: Methylphenidate (5
RxNorm normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (5 mg every 2 hours as needed, maximum of four capsules a day for 7 days)
Trial: 16648508
Drug: Placebo (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (every 2 hours as needed, maximum of four capsules a day for 7 days)
Trial: 16249975
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg/day, p.o.
Trial: 16249975
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg/day, p.o. + famotidine 40 mg/day, p.o.
Trial: 16249975
Drug: Rabeprazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole treatment (before treatment)
Trial: 16249975
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (before treatment)
Trial: 11729332
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) every-other-day
Trial: 3119340
Drug: Nitroglycerin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.5 mg)
Trial: 27966192
Drug: SDM intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDM intervention (12-h SDM training program for physicians in combination with decision board use)
Trial: 27595402
Drug: Transperineal prostatic
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperineal prostatic block (TPPB) with 10 ml 2% prilocaine (Group-I)
Trial: 27595402
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel (10 ml 2% lidocaine) followed by periprostatic nerve blockage (PPNB) with 10 ml 2% prilocaine (Group-II)
Trial: 18689371
Drug: Daily 500
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily 500 mcg phylloquinone supplementation for 3 years
Trial: 15331394
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) + oral placebo
Trial: 15331394
Drug: Diacerein 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 100 mg/day + IA injections of saline solution
Trial: 15331394
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo + IA injections of saline solution
Trial: 11425926
Drug: Interferon-beta-1a, 22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a, 22 mcg tiw
Trial: 11425926
Drug: Interferon-beta-1a, 44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a, 44 mcg tiw
Trial: 2441162
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg S-9780
Trial: 2441162
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg S-9780
Trial: 2441162
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg S-9780
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation at 50 mg/kg
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation at 100 mg/kg
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation at 300 mg/kg
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation at 500 mg/kg
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation at 56.3 mg/kg
Trial: 28484897
Drug: Dietary vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary vitamin E supplementation from 56.3 to 588.4 mg/kg
Trial: 26559363
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for depression group
Trial: 26559363
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for schizophrenia group
Trial: 24474233
Drug: Mesalazine (Pentasa®)
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine (Pentasa®) 2 g sachet once daily
Trial: 24474233
Drug: Mesalazine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (twice daily in tablets)
Trial: 21199957
Drug: Bupropion treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion treatment for 8 weeks
Trial: 10919933
Drug: High-isoflavone dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone dietary treatment
Trial: 10919933
Drug: Low-isoflavone dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone dietary treatment
Trial: 31922372
Drug: Magnetic seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic seizure therapy (high frequency 100 Hz, medium frequency 50 or 60 Hz, low frequency 25 Hz)
Trial: 31922372
Drug: Magnetic seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic seizure therapy (high frequency over vertex)
Trial: 28095051
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Treatment and Control)
Trial: 15109188
Drug: Vital capacity
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital capacity rapid inhalation induction at 8% sevoflurane (Group VC8)
Trial: 15109188
Drug: Vital capacity
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital capacity rapid inhalation induction at 4.5% sevoflurane (Group VC4.5)
Trial: 15109188
Drug: Conventional stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional stepwise inhalation induction (Group C)
Trial: 11687365
Drug: Topical plus
RxNorm normalized name: Revolution Plus Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical plus intracameral anesthesia
Trial: 9174114
Drug: LY293111 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY293111 48 mg
Trial: 9174114
Drug: LY293111 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY293111 200 mg
Trial: 7697690
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/d for 4 weeks
Trial: 7697690
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/d for 4 weeks
Trial: 7697690
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/d for 6 months
Trial: 7697690
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every other day for 6 months
Trial: 3310639
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (800 mg elemental calcium per day)
Trial: 3310639
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (800 mg elemental calcium per day)
Trial: 28603176
Drug: BM-MNC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM-MNC treatment
Trial: 24176229
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg choline daily for 9 months
Trial: 18077211
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure (nCPAP) treatment
Trial: 9864075
Drug: Fluvoxamine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 300 mg/day + Placebo
Trial: 9864075
Drug: Fluvoxamine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 300 mg/day + Pindolol 7.5 mg/day
Trial: 7838642
Drug: Rapid injection
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid injection of indomethacin (3 doses)
Trial: 7838642
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of indomethacin (over 36 hours)
Trial: 687017
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without ECMO
Trial: 25257273
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (oral antibiotics, mometasone furoate nasal spray, leukotriene receptor antagonist, mucoactive medications) for 3 months
Trial: 25257273
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (drug therapy plus negative pressure of sputum aspiration) for 3 months
Trial: 25257273
Drug: Coblation adenotonsillectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coblation adenotonsillectomy after 3 days conservative treatment and postoperative drug therapy for 2 weeks (B2 subgroup)
Trial: 25257273
Drug: Coblation adenotonsillectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coblation adenotonsillectomy after 2 weeks conservative treatment and postoperative drug therapy for 3 months (B3 subgroup)
Trial: 25257273
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy for 3 months (A1 subgroup)
Trial: 25257273
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for 3 months (B1 subgroup)
Trial: 7641173
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of ioversol 320 mg I/ml
Trial: 7641173
Drug: 75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 ml of ioversol 320 mg I/ml
Trial: 7641173
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of ioversol 320 mg I/ml
Trial: 7641173
Drug: 120 ml
RxNorm normalized name: 120 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 ml of ioversol 320 mg I/ml
Trial: 22728911
Drug: SMS reminder
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminder at 10-12 weeks post-treatment
Trial: 18755220
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of PEG-IFN alpha-2b and boceprevir